Altimmune (ALT) Other Non Operating Income (2010 - 2026)
Altimmune (ALT) posted quarterly Other Non Operating Income of -$152000.0 for Q1 2026, down 1113.33% year-over-year from $15000.0 in Q1 2025, and down 109.61% quarter-over-quarter from $1.6 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Other Non Operating Income (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Other Non Operating Income for 17 consecutive years, with -$152000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 1113.33% year-over-year to -$152000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 30.99% YoY), while the FY2025 annual figure was $1.4 million, up 52.8% from the prior year.
- Other Non Operating Income eased to -$152000.0 in Q1 2026 per ALT's latest filing, from $1.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.6 million in Q4 2025 and bottomed at -$217000.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged $136941.2 across 5 years, with a median of $18000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non Operating Income surged 4890.0% — and 2026, when it slumped 1113.33%.
- Altimmune's Other Non Operating Income stood at -$217000.0 in 2022, then soared by 109.22% to $20000.0 in 2023, then soared by 4890.0% to $998000.0 in 2024, then surged by 58.42% to $1.6 million in 2025, then tumbled by 109.61% to -$152000.0 in 2026.
- Business Quant data shows ALT's Other Non Operating Income at -$152000.0 in Q1 2026, $1.6 million in Q4 2025, and -$86000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Altimmune | 608.26 Mn | 608.26 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,000.00 |
| Mar 31, 2026 | -152,000.00 |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -92,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 998,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 113,000.00 |
| Mar 31, 2023 | 19,000.00 |
| Dec 31, 2022 | -217,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 25,000.00 |
| Mar 31, 2022 | 110,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Sep 30, 2021 | -286,000.00 |